Compare Figure Technology Solutions Inc. Class A Common Stock (FIGR) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance

FIGR trades at $27.25, down 4.25% over 24 hours, with a bearish technical signal from moving averages. The company reported strong fundamentals: Q2 2026 EPS beat expectations at $0.37, revenue grew to $509.30M in 2025, and net income margin improved to 33.83% in 2026. Recent news highlights the Kiavi acquisition and partnership with Sierra to enhance AI-driven lending capabilities, supporting growth in loan volumes.

Wall Street maintains a bullish outlook with a consensus price target of $50.00, implying significant upside. However, risks include recent earnings misses in Q4 2025 and Q1 2026, negative operating cash flow projected for 2026, and competitive pressures in the lending infrastructure space. The stock's high P/E of 28.52 warrants caution amid growth execution uncertainties.

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.